Login to Your Account



Deal First, then $33M Series A: Loxo ‘Upends’ The Traditional Way

By Randy Osborne
Staff Writer

Friday, October 4, 2013
Series A funding of $33 million will let Loxo Oncology Inc. move its lead compound through proof-of-concept research and push another into the clinic over the next three years or so, but the Delaware-incorporated firm still is not disclosing more about them.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription